DK3912987T3 - Oprensningsplatform til bispecifikke antistoffer - Google Patents

Oprensningsplatform til bispecifikke antistoffer Download PDF

Info

Publication number
DK3912987T3
DK3912987T3 DK21170436.6T DK21170436T DK3912987T3 DK 3912987 T3 DK3912987 T3 DK 3912987T3 DK 21170436 T DK21170436 T DK 21170436T DK 3912987 T3 DK3912987 T3 DK 3912987T3
Authority
DK
Denmark
Prior art keywords
bispecific antibodies
purification platform
purification
platform
bispecific
Prior art date
Application number
DK21170436.6T
Other languages
English (en)
Inventor
Andrew Tustian
Christine Endicott
Benjamin Adams
John Mattila
Hanne Bak
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3912987T3 publication Critical patent/DK3912987T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • B01D15/3819Affinity chromatography of the nucleic acid-nucleic acid binding protein type
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/26Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804Affinity chromatography
    • B01D15/3828Ligand exchange chromatography, e.g. complexation, chelation or metal interaction chromatography
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/26Cation exchangers for chromatographic processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/165Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/22Affinity chromatography or related techniques based upon selective absorption processes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
DK21170436.6T 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer DK3912987T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462029463P 2014-07-26 2014-07-26
EP15750182.6A EP3172221B1 (en) 2014-07-26 2015-07-24 Purification platform for bispecific antibodies

Publications (1)

Publication Number Publication Date
DK3912987T3 true DK3912987T3 (da) 2023-05-01

Family

ID=53836215

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15750182.6T DK3172221T3 (da) 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer
DK21170436.6T DK3912987T3 (da) 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK15750182.6T DK3172221T3 (da) 2014-07-26 2015-07-24 Oprensningsplatform til bispecifikke antistoffer

Country Status (20)

Country Link
US (1) US10626142B2 (da)
EP (2) EP3172221B1 (da)
JP (1) JP6702967B2 (da)
KR (1) KR102440737B1 (da)
CN (1) CN107074906B (da)
AR (1) AR101262A1 (da)
AU (1) AU2015298156B2 (da)
CA (1) CA2955618A1 (da)
DK (2) DK3172221T3 (da)
EA (1) EA036154B1 (da)
ES (2) ES2942533T3 (da)
FI (1) FI3912987T3 (da)
IL (1) IL255198B (da)
MX (1) MX2017001217A (da)
MY (1) MY187051A (da)
PL (2) PL3912987T3 (da)
SG (2) SG10201900661YA (da)
TW (1) TWI704155B (da)
WO (1) WO2016018740A2 (da)
ZA (1) ZA201700622B (da)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
SG10201605394SA (en) 2007-09-26 2016-08-30 Chugai Pharmaceutical Co Ltd Modified Antibody Constant Region
EP3689912A1 (en) 2007-09-26 2020-08-05 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
BR112013013311A2 (pt) 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd agente terapêutico de indução de citotoxicidade
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
US11566082B2 (en) 2014-11-17 2023-01-31 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
EP3279216A4 (en) 2015-04-01 2019-06-19 Chugai Seiyaku Kabushiki Kaisha PROCESS FOR PREPARING POLYPEPTIDE HETERO OLIGOMER
CN107614014B (zh) * 2015-05-28 2022-07-12 生物辐射实验室股份有限公司 亲和配体及其相关方法
AU2016381992B2 (en) * 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
US10654887B2 (en) 2016-05-11 2020-05-19 Ge Healthcare Bio-Process R&D Ab Separation matrix
US10703774B2 (en) 2016-09-30 2020-07-07 Ge Healthcare Bioprocess R&D Ab Separation method
ES2874974T3 (es) 2016-05-11 2021-11-05 Cytiva Bioprocess R & D Ab Matriz de separación
US10730908B2 (en) 2016-05-11 2020-08-04 Ge Healthcare Bioprocess R&D Ab Separation method
JP7106187B2 (ja) 2016-05-11 2022-07-26 サイティバ・バイオプロセス・アールアンドディ・アクチボラグ 分離マトリックスを保存する方法
US10889615B2 (en) 2016-05-11 2021-01-12 Cytiva Bioprocess R&D Ab Mutated immunoglobulin-binding polypeptides
CN109311948B (zh) 2016-05-11 2022-09-16 思拓凡生物工艺研发有限公司 清洁和/或消毒分离基质的方法
AR108800A1 (es) * 2016-06-17 2018-09-26 Genentech Inc Purificación de anticuerpos multiespecíficos
KR101933656B1 (ko) 2016-08-20 2018-12-28 (주) 아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
WO2018038469A1 (ko) * 2016-08-20 2018-03-01 (주)아이벤트러스 목적하는 이중특이성 항체의 선택적 생산 확인 방법
EP3769083A1 (en) 2018-03-21 2021-01-27 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
GB201805142D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Bioprocess R&D Ab Separation method
KR20210045413A (ko) * 2018-08-17 2021-04-26 리제너론 파마슈티칼스 인코포레이티드 다량체 단백질의 양 및 순도를 측정하기 위한 방법 및 크로마토그래피 시스템
JPWO2020066270A1 (ja) * 2018-09-28 2021-08-30 株式会社カネカ κ鎖可変領域を含む抗体および/または抗体断片の製造方法
WO2020092499A1 (en) 2018-10-31 2020-05-07 Regeneron Pharmaceuticals, Inc. Method and system of identifying and quantifying a protein
MA55134A (fr) * 2018-11-21 2021-09-29 Regeneron Pharma Anticorps anti-staphylococcus et leurs utilisations
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
SG11202106393SA (en) 2018-12-24 2021-07-29 Sanofi Sa Pseudofab-based multispecific binding proteins
CA3140075A1 (en) 2019-06-11 2020-12-17 Regeneron Pharmaceuticals, Inc. Anti-pcrv antibodies that bind pcrv, compositions comprising anti-pcrv antibodies, and methods of use thereof
EA202290040A1 (ru) * 2019-06-13 2022-03-05 Ридженерон Фармасьютикалз, Инк. Способы удаления нежелательных компонентов в многостадийных хроматографических процессах
CN114206924A (zh) 2019-12-06 2022-03-18 瑞泽恩制药公司 抗vegf蛋白组合物及其制备方法
WO2021130717A1 (ko) * 2019-12-26 2021-07-01 에이비엘바이오 주식회사 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법
KR20210084054A (ko) 2019-12-27 2021-07-07 케이에스광학주식회사 투명한 방탄 적층 구조물
US20240084025A1 (en) * 2021-01-25 2024-03-14 Yuhan Corporation Methods for purifying an anti-4-1bb/anti-her2 bispecific antibody
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies
KR20230057280A (ko) * 2021-10-19 2023-04-28 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 정제방법
WO2023247468A2 (en) * 2022-06-22 2023-12-28 Puridify Limited Kappa light chain-binding convection matrix

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
GB8626413D0 (en) 1986-11-05 1986-12-03 Gilliland L K Antibodies
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
EP0826695B1 (de) 1996-09-03 2001-12-12 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Zerstörung von kontaminierenden Tumorzellen in Stammzelltransplantaten mit bispezifischen Antikörpern
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
WO2000018435A1 (de) 1998-09-25 2000-04-06 Horst Lindhofer Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
US7169903B2 (en) 2001-12-21 2007-01-30 Biosynexus Incorporated Multifunctional monoclonal antibodies directed to peptidoglycan of gram-positive bacteria
US20030224000A1 (en) 2001-12-21 2003-12-04 Kokai-Kun John Fitzgerald Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
EP2388274A1 (en) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Methods of purifying anti A Beta antibodies
US7923538B2 (en) 2005-07-22 2011-04-12 Kyowa Hakko Kirin Co., Ltd Recombinant antibody composition
CL2008000883A1 (es) * 2007-03-28 2008-10-03 Wyeth6 3 Metodo de deteccion de compuestos capaces de antagonizar la senalizacion de il-17f/il-17a; compuesto identificado por dicho metodo; uso de una cantidad de un antagonista de senalizacion de il-17f/il-17a, composicion farmaceutica que comprende dicho a
SG149759A1 (en) * 2007-07-10 2009-02-27 Millipore Corp Media for affinity chromatography
WO2010030222A1 (en) * 2008-09-12 2010-03-18 Ge Healthcare Bio-Sciences Ab Enhanced protein aggregate removal with multimodal anion exchangers in the presence of protein-excluded zwitterions
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL2975051T3 (pl) * 2009-06-26 2021-09-20 Regeneron Pharmaceuticals, Inc. Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny
RU2606264C2 (ru) * 2009-12-25 2017-01-10 Чугаи Сеияку Кабушики Каиша Способ полипептидной модификации для очистки полипептидных мультимеров
BR112013013311A2 (pt) * 2010-11-30 2017-09-19 Chugai Pharmaceutical Co Ltd agente terapêutico de indução de citotoxicidade
EP2500073A1 (en) * 2011-03-17 2012-09-19 ChromaCon AG Method for identification and purification of multi-specific polypeptides
US9815909B2 (en) * 2012-03-13 2017-11-14 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
AU2013322710A1 (en) * 2012-09-25 2015-04-16 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos

Also Published As

Publication number Publication date
KR102440737B1 (ko) 2022-09-06
MY187051A (en) 2021-08-27
ES2881026T3 (es) 2021-11-26
EP3912987B9 (en) 2023-05-31
AU2015298156B2 (en) 2020-07-16
PL3912987T3 (pl) 2023-07-24
AU2015298156A1 (en) 2017-02-23
IL255198A0 (en) 2017-12-31
FI3912987T3 (fi) 2023-06-19
CN107074906B (zh) 2021-05-14
SG11201700157VA (en) 2017-02-27
WO2016018740A3 (en) 2016-03-17
EP3172221A2 (en) 2017-05-31
EP3912987A1 (en) 2021-11-24
ZA201700622B (en) 2020-05-27
NZ728700A (en) 2023-09-29
US20160024147A1 (en) 2016-01-28
US10626142B2 (en) 2020-04-21
WO2016018740A8 (en) 2021-06-10
ES2942533T3 (es) 2023-06-02
JP2017524740A (ja) 2017-08-31
EA036154B1 (ru) 2020-10-06
AR101262A1 (es) 2016-12-07
PL3172221T3 (pl) 2021-12-27
EA201790247A1 (ru) 2017-08-31
EP3172221B1 (en) 2021-07-07
BR112017001443A2 (pt) 2017-12-05
JP6702967B2 (ja) 2020-06-03
TW201617359A (zh) 2016-05-16
CA2955618A1 (en) 2016-02-04
IL255198B (en) 2022-04-01
MX2017001217A (es) 2017-05-03
SG10201900661YA (en) 2019-02-27
CN107074906A (zh) 2017-08-18
TWI704155B (zh) 2020-09-11
EP3912987B1 (en) 2023-03-22
KR20170035941A (ko) 2017-03-31
DK3172221T3 (da) 2021-08-09
WO2016018740A2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IL255198B (en) A purification platform for bispecific antibodies
NL301117I2 (nl) trastuzumab deruxtecan
CL2018000370A1 (es) Nuevos anticuerpos anti-pd-1
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3344654T3 (da) Anti-lag-3-antistoffer
DK3332006T3 (da) Hidtil ukendte anti-PD-L1-antistoffer
BR112017002234A2 (pt) anticorpos anti-pd-l1
DK3126395T3 (da) Multispecifikke antistoffer
DK3191517T3 (da) Krydsreaktive siglec-antistoffer
DK3266792T3 (da) Fremgangsmåde til peptidsyntese
DK3072835T3 (da) Fremgangsmåde til fremføring
DK3131928T3 (da) Trifunktionelt antigenbindende molekyle
DK3350218T3 (da) Polyomavirus-neutraliserende antistoffer
MA40901A (fr) Anticorps bispécifiques anti-tnf/anti-il-3
DK3125898T3 (da) Farmakofor til trail-induktion
DK3250593T3 (da) Anti-transthyretin-antistoffer
DK3215530T3 (da) Forbedrede il-6 antistoffer
DK3209541T3 (da) Sadel til et køretøj
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3197589T3 (da) Fremgangsmåde til oprensning af væsker
UA29847S (uk) Посудина для закусок
UA29846S (uk) Посудина для закусок
TH1601006445A (th) โครงสร้างสำหรับบรรจุของยานพาหนะ
FR3031123B1 (fr) Montant pour cloison
TH1701000091A (th) วิธีการสำหรับการยึดติดผ้า-อิลาสโตเมอร์